Comments
Pharma major Hetero has said that Phase III trials of its Movfor (Molnupiravir), an investigational oral antiviral Covid-19 medicine, are positive.
The results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually this week, has demonstrated that Molnupiravir along with Standard of Care (SoC) reduced the risk of hospitalisation by over 65 per cent, compared to SoC alone.
Related Stories
Covid-19: Hetero launches Movfor, Molnupiravir capsules to treat high-risk adult patients
Gets DCGI nod to manufacture and market an investigational oral antiviral.“Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within 5 days of administering the antiviral drug. There were no fatalities reported during the study,” the company has said in a statement.
The study enrolled 1,218 eligible patients within five days of the onset of Covid-19 symptoms and were administered with Molnupiravir capsules (800 mg twice daily) for five days.
The SoC medication was administered thru the period as defined by the Indian Council of Medical Research (ICMR) in its guidelines during the medication.
Hetero has tied up with MSD last year for the manufacturing and distribution of the drug. Under this licensing deal, Hetero was allowed to expand access of Molnupiravir in India and in other low-and middle-income countries, after getting necessary approvals from the respective local regulatory agencies.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.